Shanghai Henlius Biotech, Inc.

SEHK:2696 Rapporto sulle azioni

Cap. di mercato: HK$11.8b

Shanghai Henlius Biotech Gestione

Gestione criteri di controllo 2/4

Shanghai Henlius Biotech's CEO is Jason Zhu, appointed in Jul 2023, has a tenure of 1.33 years. total yearly compensation is CN¥9.26M, comprised of 87.8% salary and 12.2% bonuses, including company stock and options. directly owns 0.009% of the company’s shares, worth HK$1.09M. The average tenure of the management team and the board of directors is 2.3 years and 5.2 years respectively.

Informazioni chiave

Jason Zhu

Amministratore delegato

CN¥9.3m

Compenso totale

Percentuale dello stipendio del CEO87.8%
Mandato del CEO1.3yrs
Proprietà del CEO0.009%
Durata media del management2.3yrs
Durata media del Consiglio di amministrazione5.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

May 25
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25
Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Mar 10
Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Dec 31
Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25
The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 18
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Aug 03
Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

May 31
Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Apr 06
Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 22
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jason Zhu rispetto agli utili di Shanghai Henlius Biotech?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

CN¥692m

Mar 31 2024n/an/a

CN¥619m

Dec 31 2023CN¥9mCN¥8m

CN¥546m

Compensazione vs Mercato: Jason's total compensation ($USD1.31M) is above average for companies of similar size in the Hong Kong market ($USD496.15K).

Compensazione vs guadagni: Insufficient data to compare Jason's compensation with company performance.


AMMINISTRATORE DELEGATO

Jason Zhu (45 yo)

1.3yrs

Mandato

CN¥9,261,000

Compensazione

Dr. Jun Zhu, also known as Jason, had been Chief Financial Officer at Shanghai Henlius Biotech, Inc. since May 1, 2023 until July 1, 2024 and served as its President since November 30, 2021 until October 1...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Wenjie Zhang
Executive Chairman of the Board4.8yrsCN¥12.58mNessun dato
Jun Zhu
CEO & Executive Director1.3yrsCN¥9.26m0.0092%
HK$ 1.1m
Huang Wei
President1.1yrsNessun datoNessun dato
Shi-Kau Liu
Co-founder & Head of Strategy Advisory Committee14.8yrsCN¥6.21m0.44%
HK$ 52.6m
Wei-Dong Jiang
Co-Founder & Co-Head of Innovative Advisory Committee14.8yrsNessun dato0.13%
HK$ 15.7m
Yingbo Mao
VP & CFOless than a yearNessun datoNessun dato
Jifeng Zhang
CTO & Senior VP1.9yrsNessun datoNessun dato
Miaojie Chen
Vice President of Legal & Compliance Department1.8yrsNessun datoNessun dato
Yan Wang
Deputy GM of Public Relations & Joint Company Secretary3yrsNessun datoNessun dato
Wallis Zeng
VP of Sales & Oncology Business Unit4.8yrsNessun datoNessun dato
Junhua Li
VP & Chief Human Resource Officer2.6yrsNessun datoNessun dato
Xinjun Guo
Senior Vice Presidentno dataNessun datoNessun dato

2.3yrs

Durata media

52yo

Età media

Gestione esperta: 2696's management team is considered experienced (2.3 years average tenure).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Wenjie Zhang
Executive Chairman of the Board4.8yrsCN¥12.58mNessun dato
Jun Zhu
CEO & Executive Director1.3yrsCN¥9.26m0.0092%
HK$ 1.1m
Tak Young So
Independent Non-Executive Director5.2yrsCN¥258.00kNessun dato
Qiyu Chen
Non-Executive Director11.8yrsNessun datoNessun dato
Guoping Zhao
Independent Non-Executive Director5.2yrsCN¥258.00kNessun dato
Xiaohui Guan
Non-Executive Director5.9yrsNessun datoNessun dato
K. Christopher Garcia
Member of Scientific Advisory Board1.3yrsNessun datoNessun dato
Yifang Wu
Non-Executive Director9.4yrsNessun datoNessun dato
Deyong Wen
Non-Executive Director2.3yrsNessun datoNessun dato
Lik Yuen Chan
Independent Non-Executive Director5.2yrsCN¥258.00kNessun dato
Ruilin Song
Independent Non-Executive Director5.2yrsCN¥258.00kNessun dato
Rongli Feng
Chairman of Supervisory Board4.6yrsNessun datoNessun dato

5.2yrs

Durata media

53yo

Età media

Consiglio di amministrazione esperto: 2696's board of directors are considered experienced (5.2 years average tenure).